Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

NCT07517640 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: furmonertinib
PROCEDURE: ablation
RADIATION: stereotactic body radiotherapy

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China